SILICON PHTHALOCYANINE COMPLEX, PREPARATION METHOD AND MEDICINAL APPLICATION THEREOF
申请人:Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.
公开号:US20170002028A1
公开(公告)日:2017-01-05
The present invention relates to a silicon phthalocyanine complex, the preparation method and the medicinal application thereof. The present invention particularly relates to a silicon phthalocyanine complex of formula (I), the preparation method thereof and a pharmaceutical composition comprising the same, as well as the use thereof as a photosensitizer, in particular the use in the treatment of cancers, wherein each substituent in formula (I) is the same as defined in the description.
[EN] BENZYLBENZENE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS DE BENZYLBENZÈNE ET PROCÉDÉS D'UTILISATION
申请人:THERACOS INC
公开号:WO2009026537A1
公开(公告)日:2009-02-26
Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
Tandem Functionalization in a Highly Branched Polymer with Layered Structure
作者:Xiaosong Cao、Yi Shi、Weiping Gan、Haifeng Gao
DOI:10.1002/chem.201800683
日期:2018.4.17
hyperbranched polymer with multilayer structure was developed to demonstrate the possibility of highly efficient tandem functionalization reactions at different domains within one nanostructured platform. The polymer scaffold was constructed by chain‐growth copper‐catalyzed azide–alkyne cycloaddition polymerization of three functional monomers with sequential monomer addition in one pot. Subsequent reactions
[EN] MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN<br/>[FR] DÉRIVÉS DE MORPHINANE POUR LE TRAITEMENT DE LA DOULEUR NEUROPATHIQUE
申请人:NEKTAR THERAPEUTICS
公开号:WO2016182840A1
公开(公告)日:2016-11-17
The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of the invention, a compound according to Formula I is provided: and pharmaceutically acceptable salts thereof, wherein R1-R11 are as described herein.
Polyethylene glycol-based homologated ligands for nicotinic acetylcholine receptors☆
作者:Bradley A. Scates、Bethany L. Lashbrook、Benjamin C. Chastain、Kaoru Tominaga、Brandon T. Elliott、Nicholas J. Theising、Thomas A. Baker、Richard W. Fitch
DOI:10.1016/j.bmc.2008.10.045
日期:2008.12.15
ethers were conjugated with three ligand series for nicotinic acetylcholine receptors. Conjugates of acetylaminocholine, the cyclic analog 1-acetyl-4,4-dimethylpiperazinium, and pyridyl ether A-84543 were prepared. Each series was found to retain significant affinity at nicotinic receptors in rat cerebral cortex with tethers of up to six PEG units. Such compounds are hydrophilic ligands which may serve